Retapamulin
As of the edition of 20 October 2026, Retapamulin is a small molecule: marketed, first approved in 2007 (US); US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2007
- Kind
- Small molecule
- Brand name
- Altabax
- First approved
- 12 April 2007 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Almirall
- Withdrawn from market
- 25 February 2019 (in some regions)
- Registered trials
- 16, 3 stopped early
- Disease areas
- Infections; Skin and connective tissue; Inherited and neonatal; Immune system
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Almirall.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 5 | 5 | 0 | 0 |
| Phase 4 | 6 | 4 | 0 | 2 |
| All trials | 16 |